Jiang et al. [22] studied the use of placenta-derived MSCs in treating type 2 diabetes mellitus (T2DM), which resulted in a decrease of ≥ 50% in insulin requirements and improvement in kidney and heart function to some extent. This evidence concerns the gene INS and type 2 diabetes mellitus.